INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Inmune Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.54−0.03 (-1.91%)
Close on Oct 19, 2026
- Market cap
- $41.15M
- P/E (TTM)
- –
- Dividend yield
- –
Inmune Bio, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- -40390.0%
- Net margin
- -36832.0%
- Return on equity, FY2025
- -165.2%
Financial strength
- Current ratio
- 4.04
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 312.6%
Valuation
- P/E ratio
- –
- Price to sales
- 822.93
- Price to book
- 2.02
- Dividend yield
- –